Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azzalure for Lateral Canthal Lines (Crow's Feet)
NCT01308060Phase 3Completed
- Sponsor
- Galderma
- Start
- Jan 2011
- Primary completion
- May 2012
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in lateral canthal rhytides comparing Azzalure (Botulinum Toxin Type A) with Placebo (2 arms). Primary endpoint: Number of Responders on the Severity of Lateral Canthal Lines at Maximum Smile at 4 weeks. Started Jan 2011; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
lateral canthal rhytides
Beyond the preview
Go deeper on NCT01308060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01308060.